PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 129 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,155,788 | -55.2% | 429,004 | -25.8% | 0.00% | -50.0% |
| Q2 2023 | $15,964,941 | -55.8% | 578,021 | -63.2% | 0.00% | -50.0% |
| Q1 2023 | $36,121,730 | +35.8% | 1,570,510 | -35.6% | 0.00% | +33.3% |
| Q4 2022 | $26,604,222 | +41.7% | 2,438,517 | +9.5% | 0.00% | 0.0% |
| Q3 2022 | $18,777,000 | +33.6% | 2,227,575 | +25.4% | 0.00% | +50.0% |
| Q2 2022 | $14,050,000 | -55.6% | 1,776,452 | +32.9% | 0.00% | -50.0% |
| Q1 2022 | $31,661,000 | +761.8% | 1,337,103 | +1144.8% | 0.00% | – |
| Q4 2021 | $3,674,000 | -56.3% | 107,416 | -77.4% | 0.00% | -100.0% |
| Q3 2021 | $8,405,000 | +168.3% | 474,315 | +579.2% | 0.00% | – |
| Q2 2021 | $3,133,000 | +2447.2% | 69,830 | +1378.5% | 0.00% | – |
| Q1 2021 | $123,000 | -81.8% | 4,723 | -85.9% | 0.00% | – |
| Q4 2020 | $675,000 | +332.7% | 33,489 | +321.5% | 0.00% | – |
| Q3 2020 | $156,000 | -17.9% | 7,945 | -26.3% | 0.00% | – |
| Q2 2020 | $190,000 | +1800.0% | 10,778 | +690.8% | 0.00% | – |
| Q1 2020 | $10,000 | -95.7% | 1,363 | -95.9% | 0.00% | – |
| Q4 2019 | $235,000 | -84.0% | 33,329 | -72.7% | 0.00% | – |
| Q3 2019 | $1,465,000 | +18212.5% | 122,003 | +18498.0% | 0.00% | – |
| Q2 2019 | $8,000 | -86.0% | 656 | -85.4% | 0.00% | – |
| Q1 2019 | $57,000 | +90.0% | 4,487 | +1.2% | 0.00% | – |
| Q4 2018 | $30,000 | -87.1% | 4,433 | -80.4% | 0.00% | – |
| Q3 2018 | $233,000 | -24.4% | 22,637 | -50.4% | 0.00% | – |
| Q2 2018 | $308,000 | +27.3% | 45,680 | +62.1% | 0.00% | – |
| Q1 2018 | $242,000 | -57.8% | 28,177 | +2.1% | 0.00% | – |
| Q4 2017 | $574,000 | +68.3% | 27,584 | +43.1% | 0.00% | – |
| Q3 2017 | $341,000 | +258.9% | 19,281 | +130.2% | 0.00% | – |
| Q2 2017 | $95,000 | -62.6% | 8,377 | -57.7% | 0.00% | – |
| Q1 2017 | $254,000 | -74.7% | 19,802 | -56.5% | 0.00% | – |
| Q4 2016 | $1,002,000 | +24950.0% | 45,556 | +22678.0% | 0.00% | – |
| Q3 2016 | $4,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |